Association of Benign Prostate Hyperplasia with Polymorphisms in VDR, CYP17, and SRD5A2 Genes among Lebanese Men |
El Ezzi, Asmahan Ali
(Radioimmunoassay Laboratory, Lebanese Atomic Energy Commission)
Zaidan, Wissam Rateeb (Radioimmunoassay Laboratory, Lebanese Atomic Energy Commission) El-Saidi, Mohammed Ahmed (Office of Research, Utah Valley University) Al-Ahmadieh, Nabil (Department of Urology, Mount Lebanon Hospital) Mortenson, Jeffrey Benjamin (Department of Biology, Utah Valley University) Kuddus, Ruhul Haque (Department of Biology, Utah Valley University) |
1 | Tayeb MT, Clark C, Haites NE, et al. (2004). Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J, 25, 447- 51. |
2 | Taylor JA, Hirvonen A, Watson M, et al (1996). Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res, 56, 4108-10. |
3 | Tigli H, Yazici H, Dalay N (2003). CYP17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia," Res Commun Mol Pathol Pharmacol, 113-4, 307-14. |
4 | Verhamme KM, Dielemana JP, Bleuminka GS, et al (2002). Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-The Triumph Project. Eur Urol, 42, 323-8. DOI ScienceOn |
5 | Platz EA, Kawachi I, Rimm EB, Willett WC, Giovannucci E. (2000). Race, ethnicity and benign prostatic hyperplasia in the health professionals' follow-up study. J Urol, 163, 490-5. DOI ScienceOn |
6 | Oh JJ, Byun SS, Lee SE et al (2014). Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population. Gene, 533, 86-93. DOI ScienceOn |
7 | Orsted DD, Bojesen SE (2013). The link between benign prostatic hyperplasia and prostate cancer, Nature Rev Urol, 10, 49-54. |
8 | Pearson JD, Lei HH, Beaty TH, et al (2003). Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology, 61, 781-5. DOI ScienceOn |
9 | Rajender S, Vijayalakshmi K, Pooja S et al (2009). Longer (TA) n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. J Androl, 30, 703-10 DOI ScienceOn |
10 | Roberts RO, Bergstralh EJ, Farmer SA, et al (2006). Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia. Prostate, 66, 392-404. DOI ScienceOn |
11 | Ruan L, Zhong WD, Li ZM, Hua X (2011). Relationship between vitamin D receptor gene Fok I polymorphisms and benign prostatic hyperplasia complicated by histological prostatitis. Zhonghua Nan Ke Xue, 17, 880-3. |
12 | Konwar R, Chattopadhyay N, Bid HK (2008). Genetic polymorphism and pathogenesis of benign prostatic hyperplasia. BJU Int, 102, 536-44. DOI ScienceOn |
13 | Salam MT, Ursin G, Skinner EG, Dessissa T, Reichardt JK (2005). Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol, 23, 246-53. DOI ScienceOn |
14 | Schatzl G, Gsur A, Bernhofer G, et al (2001). Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. Urol, 57, 567-72. DOI ScienceOn |
15 | Sobti RC, Gupta L, Thakur H (2009). CYP17 gene polymorphism and its association in north Indian prostate cancer patients. Anticancer Res, 29, 1659-63 |
16 | Izmirli M, Arikan B, Bayazit Y, Alptekin D (2011). Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men. Asian Pac J Cancer Prev, 12, 731- 3. |
17 | Kehinde EO, Sheikh M, Mojimoniyi OA, et al (2003). High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: the clinician's dilemma. BJU Int, 91, 618-22. DOI ScienceOn |
18 | Li J, Coates RJ, Gwinn M, Khoury MJ, (2010). Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review. Am J Epidemiol, 171, 1-13. DOI ScienceOn |
19 | Madigan MP, Guo YT, Deng J, et al (2003). CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int J Cancer, 107, 271-5. DOI ScienceOn |
20 | Manchanda PK, Konwar R, Nayak VL, Singh V, Bid HK (2010). Association of genetic variants of the vitamin D receptor (VDR) gene, (Fok-1, Taq-1 and Bsm-I) with susceptibility of benign prostate hyperplasia in a North Indian population. Asian Pac J Cancer Prev, 11, 1005-8. |
21 | McConnell J, Abrams P, Denis L, Khoury S, Roehrborn C, eds (2006). Male Lower Urinary Tract Dysfunction: Evaluation and Management. Paris, France, Health Publ. |
22 | Mullan RJ, Bergstralh EJ, Farmer AS, et al (2006). Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men. Urol, 67, 300-05. DOI ScienceOn |
23 | Dwivedi S, Goel A, Natu SM, et al (2011). Diagnostic and prognostic of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. Asian Pac J Cancer Prev, 12, 1843-8. |
24 | Falleti E, Bitetto D, Fabris C, et al (2010). Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol, 16, 3016-24. DOI |
25 | Feigelson HS, Coetzee GA, Kolonel LN, Ross PK, Henderson BE (1997). Polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res, 57, 1063-65. |
26 | Gunes S, Bagci H, Sarikaya S, Bilen CY, Kara N (2007). Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia. DNA Cell Biol, 26, 873-8. DOI ScienceOn |
27 | Guo YJ, Shi ZM, Liu JD et al (2012). Meta-analysis of the relation between the VDR gene TaqI polymorphism and genetic susceptibility to prostate cancer in Asian populations. Asian Pac J Cancer Prev, 13, 4441-4. 과학기술학회마을 DOI ScienceOn |
28 | Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T (2002). Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostate hyperplasia in Japanese. Urol Int, 68, 226-31. DOI ScienceOn |
29 | Habuchi T, Suzuki T, Sasaki R, et al (2000a). Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res, 60, 305-8. |
30 | Habuchi T, Liqing Z, Suzuki T, et al (2000b). Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res, 60, 5710-13. |
31 | Anim JT, Kehinde EO, Sheikh MA, et al (2007). Serum prostate specific antigen levels in middle eastern men with subclinical prostatitis. Med Princ Pract, 16, 53-8 |
32 | Azzouzi AR, Cochand-Priollet B, Mangin P, et al (2002). Impact of constitutional genetic variation in androgen/oestrogenregulating genes on age-related changes in human prostate. Eur J Endocrinol, 147, 479-84. DOI ScienceOn |
33 | Bousema JT, Bussemakers MJ, van Houwelingen KP, et al (2000). Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol, 37, 234-8. DOI ScienceOn |
34 | Central Intelligence Agency. The World Factbook. https://www.cia.gov (accessed Dec 15, 2013). |
35 | Chaimuangraj S, Thammachoti R, Ongphiphadhanakul B, Thammavit W (2006). Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls. Asian Pac J Cancer Prev, 7, 136-9. |
36 | Chang RT, Kirby R, Challacombe BJ (2012). Is there a link between BPH and prostate cancer? Practitioner, 256, 13-6. |
37 | Aoki Y, Arai Y, Maeda H, Okubo K, Shinohara K (2001). Racial differences in cellular composition of benign prostatic hyperplasia. The Prostate, 49, 243-50. DOI ScienceOn |
38 | Karimpur-Zahmatkesh A, Farzaneh F, Pouresmaeili F et al (2013). A2 allele polymorphism of the CYP17 gene and prostate cancer risk in an Iranian population. Asian Pac J Cancer Prev, 14, 1049-52. 과학기술학회마을 DOI ScienceOn |
39 | Forrest MS, Edwards SM, Houlston R, et al (2005). Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis, 8, 95-102. DOI ScienceOn |